Altogether, our data illustrate that low dose IL-2 treatment did not alter Treg and Breg cell responses but reduced the response of antigen presenting cells, and could be the reason why low dose IL-2 only provided partial protection against diabetes. This evidence concerns the gene IL2 and diabetes mellitus.